TY - JOUR
T1 - In vitro combination between antifungals and diphenyl diselenide against Cryptococcus species
AU - Rossato, Luana
AU - Loreto, Erico S
AU - Venturini, Tarcieli P
AU - de Azevedo, Maria Isabel
AU - Al-Hatmi, Abdullah M S
AU - Santurio, Janio M
AU - Alves, Sydney H
N1 - © 2019 Blackwell Verlag GmbH.
PY - 2019/6
Y1 - 2019/6
N2 - Cryptococcus species are an encapsulated fungal pathogen that cause cryptococcal meningitis. There are limited therapeutic options for this infection. The management includes the use of different antifungals such as amphotericin B, flucytosine, or fluconazole, either alone or in combination. However, numerous therapeutic failures, as well as the limited effectiveness of such therapeutics, have been described. Diphenyl diselenide is a chemically synthesised molecule with was found to have antimicrobial activity. In this study, we evaluated the antifungal activities of fluconazole, amphotericin B and flucytosine, in combination with diphenyl diselenide against 30 clinical isolates of Cryptococcus spp. using CLSI M27-A3 method and the checkerboard microdilution technique. Our results show that the combination of flucytosine and diphenyl diselenide displayed 100% of synergism. However, when we analysed (PhSe)2 plus AMB or FLZ we observed around 70% of indifference. Our results suggest that the combination of diphenyl diselenide with other antifungal agents deserves attention as a new option for the development of alternative therapies for cryptococcosis.
AB - Cryptococcus species are an encapsulated fungal pathogen that cause cryptococcal meningitis. There are limited therapeutic options for this infection. The management includes the use of different antifungals such as amphotericin B, flucytosine, or fluconazole, either alone or in combination. However, numerous therapeutic failures, as well as the limited effectiveness of such therapeutics, have been described. Diphenyl diselenide is a chemically synthesised molecule with was found to have antimicrobial activity. In this study, we evaluated the antifungal activities of fluconazole, amphotericin B and flucytosine, in combination with diphenyl diselenide against 30 clinical isolates of Cryptococcus spp. using CLSI M27-A3 method and the checkerboard microdilution technique. Our results show that the combination of flucytosine and diphenyl diselenide displayed 100% of synergism. However, when we analysed (PhSe)2 plus AMB or FLZ we observed around 70% of indifference. Our results suggest that the combination of diphenyl diselenide with other antifungal agents deserves attention as a new option for the development of alternative therapies for cryptococcosis.
KW - Amphotericin B/pharmacology
KW - Antifungal Agents/pharmacology
KW - Benzene Derivatives/pharmacology
KW - Cryptococcosis/microbiology
KW - Cryptococcus/drug effects
KW - Drug Synergism
KW - Fluconazole/pharmacology
KW - Flucytosine/pharmacology
KW - Humans
KW - Microbial Sensitivity Tests
KW - Organoselenium Compounds/pharmacology
U2 - 10.1111/myc.12905
DO - 10.1111/myc.12905
M3 - Article
C2 - 30776159
SN - 0933-7407
VL - 62
SP - 508
EP - 512
JO - Mycoses
JF - Mycoses
IS - 6
ER -